Regional Institute of Oncology, Iaşi, Romania
Iași, Romania
Location status: Recruiting
NCT Number: NCT07237438
This study is aimed at clarifying changes in body composition during the perioperative period and identifying risk factors for skeletal muscle mass loss in patients with colorectal cancer. The investigators will asess the impact of the type of anaesthesia (total intravenous anaesthesia/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass, which will be evaluated using ultrasound, dynamometry and bioimpedance.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Iași, Romania
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
evaluate the impact of the type of anaesthesia (total intravenous anaesthesia (TIVA)/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass
evaluate the impact of the type of anaesthesia (total intravenous anaesthesia (TIVA)/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass
Time frame: From enrollment to 5 days after surgery
Ultrasonographic muscle assessment is standardised in the assessment of muscle according to the SARCUS (Sarcopenia through UltraSound) working group recommendations. Rectus femoris muscle will be evaluated at 50% distance between the anterior superior iliac spine and the superior pole of the patella, in a lying position with knees in 10°, for muscle thickness and muscle cross-sectional area (CSA). Three measurements will be taken for each data point, and the average value will be used for further analysis. The biceps brachii muscle will be evaluated at 50% distance acromioclavicular joint and the elbow crease, in a supine position. Muscle thickness can be easily defined as the maximal vertical distance between the superficial and deep fasciae.
Time frame: From enrollment to 5 days after surgery
Measuring grip strength is simple and inexpensive. Grip strength will be determined bilaterally. Each measurement will be performed three times on the left and right extremities with 20 seconds intervals between the measurements. The maximum measured value in kilograms will be used for analysis.
Time frame: From enrollment to 5 days after surgery
The bioimpedance measurements will be performed by a trained operator according to the manufacturer's recommendations. The Body Composition Monitor provides a quantitative measure of lean tissue and fat tissue mass. In contrast to earlier bioimpedance methodologies, the bioimpedance spectroscopy expresses body composition as a three-compartment model, providing overhydration, lean tissue index (LTI), and fat tissue index (FTI), whereby LTI and FTI are the respective tissue masses normalized to height squared.
Time frame: From enrollment to the patient discharge, up to 52 weeks
Time frame: 28 and 90-day mortality after surgery
Time frame: From enrollment to 5 days after surgery
Correlation between muscle strength and muscle mass using dynamometry and echography and bioimpedance at different time points
Contact information is provided by the study sponsor or research team.
Grigore T. Popa University of Medicine and Pharmacy
Other
Total Intravenous Anesthesia Versus Balanced Anesthesia on Loss of Muscle Mass After Colorectal Cancer Surgery
Acronym: TIVABAL-CRC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07321106
Advanced Colorectal Cancer, CRC
Duarte, California, United States
View Trial DetailsNCT07630961
Breast Diseases, Breast Neoplasms
Chuo Ku, Tokyo, Japan
View Trial DetailsNCT07397338
Advanced Solid Tumors, Bronchial Neoplasms
Norwich, Connecticut, United States
View Trial DetailsNCT07349537
Advanced Solid Tumors, Bronchial Neoplasms
New Haven, Connecticut, United States
View Trial Details